Even without CPACS i still think we have a lot to be excited about around your point 2. At the end of the day Anti-Cancer is what is important to the patient and we all ready know how effective this synergy is in preclinical’s. Approx a 40% improvement in over 80% of cancers tested if i recall correctly.
If we see indications that patients are improving / recovering above what we know dox does on its own (as we might expect) then i think we might see strong share price increases anyway, I'm happy to wait for CPACS news to hit in 12 months time when we are likely sitting at a much higher SP due to patient outcomes this year.
We should be back above ATHs $4.27 if we see positive anti cancer improvements here, well before CPACS.
Add to My Watchlist
What is My Watchlist?
